ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- Microsurgery guided by sequential preoperative lymphography usingEuropean journal of nuclear medicine and molecular imaging · 2017Trial
- 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Lower diffusion-derived vessel density (DDVD) measure of liver focal nodular hyperplasia than those of hepatocellular carcinoma and liver metastasis allows potential differential diagnosis: quantitative and semi-quantitative analyses of two-center data.Journal of gastrointestinal oncology · 2025Article
- Immuno-PET Imaging of CD93 Expression withMolecular pharmaceutics · 2024Article
- Underestimation of liver hemangioma perfusion fraction by standard intravoxel incoherent motion diffusion magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
- Preclinical PET Imaging and Toxicity Study of aPharmaceutics · 2023Article
- Advanced hitchhiking nanomaterials for biomedical applications.Theranostics · 2023Review
- Article
- RelatingPhysics in medicine and biology · 2022Article
- Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022Review
- Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.Science advances · 2022Article
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- ICG-ER: a new probe for photoimaging and photothermal therapy for breast cancer.American journal of translational research · 2022Article
- Unsymmetrical cyanine dye via in vivo hitchhiking endogenous albumin affords high-performance NIR-II/photoacoustic imaging and photothermal therapy.Journal of nanobiotechnology · 2021Article
- The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αMolecular imaging and biology · 2020Article
- Clinical Translation of aJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Lymphangioleiomyomatosis revealed byEuropean journal of nuclear medicine and molecular imaging · 2020Article
- 68Ga-NEB PET/CT can be a new method for diagnosing chylous fistula: Case reports of a rare complication after breast cancer surgery.Medicine · 2020Article
- Multimodality molecular imaging of the alveolar-capillary barrier in lung disease using albumin based optical and PET tracers.Molecular biomedicine · 2020Article
- 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema.Clinical nuclear medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
unlabelledSuitably labeled Evans blue dye has been successfully applied to evaluate cardiac function, vascular permeability, and lymphatic imaging in preclinical settings. This study documented the first-in-human application of 68Ga-1,4,7-triazacyclononane-N,N',N″-triacetic acid (NOTA)-NEB.
methodsThe NOTA-conjugated truncated form of Evans blue, NEB, was labeled with 68Ga and tested in BALB/C mice for dynamic PET and ex vivo biodistribution studies. Three healthy volunteers (2 men and 1 woman) underwent 90-min whole-body dynamic PET. The absorbed doses for major organs and whole body were calculated using OLINDA/EXM software. Eleven patients with focal hepatic lesions diagnosed by enhanced CT or MR imaging were subjected to whole-body PET/CT acquisitions at 30 min after intravenous injection of 111-148 MBq (3-4 mCi) of 68Ga-NEB.
resultsNEB dye was labeled with 68Ga (half-time, 68 min) with high yield and purity. After intravenous injection, 68Ga-NEB formed a complex with serum albumin, thus most of the radioactivity was retained in blood circulation. The tracer was demonstrated to be safe in both healthy volunteers and recruited patients without side effects or allergies. Among the 11 patients, hemangiomas showed much higher 68Ga-NEB signal intensity than the surrounding normal hepatic tissues, whereas no apparent difference between lesions and hepatic tissues was identified on 18F-FDG PET. All other focal hepatic lesions including hepatocellular carcinoma, hepatic cysts, and neuroendocrine tumor liver metastases showed negative 68Ga-NEB contrast to hepatic tissues.
conclusionAs a blood-pool imaging agent, 68Ga-NEB is safe to use in the clinic, and our preliminary studies demonstrate the value of differentiating hepatic hemangioma from other benign or malignant focal hepatic lesions. Easy labeling with different positron emitters of various half-lives, excellent pharmacokinetics, and imaging quality warrant further clinical applications of NEB-based PET tracers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.